Behind-the-Scenes Details of 89bio's $2.4B Deal with Roche on October 02, 2025 biotech acquisition Conditional Deal Structure Liver diseases MASH milestone payments pegozafermin Roche (company) +
Pfizer's $4.9B Metsera Deal Signals More Pharma M&A in Booming Obesity Drug Market on September 25, 2025 biotech acquisition Glucagon-Like Peptide 1 late-stage clinical development M&A Metsera Obesity Pfizer Pharma pharmaceutical market Weight Loss +
Merck Terminates Midstage Asset from $1.9B Pandion Acquisition over Lack of Clinical Benefit on July 31, 2025 asset termination Benefit biotech acquisition Clinical Trials lack of Merck Pandion +